During the month of October took place the Spanish Society of atherosclerosis (SEA 2020) Virtual meetings, promoted by Novartis. Prof. Ramon Eritja, Scientific Director of NANBIOSIS U29 Oligonucleotide Synthesis Platform (OSP) (from CIBERBBN at IQAC_CSIC), was the guess speaker in the session “Innovation and future therapeutic strategies in dyslipidemia” giving the conference entitled “How to take advantage of the body’s natural processes to create innovative therapies“, in the telematic congress of the Spanish society of atherosclerosis (SEA 2020) in the session “Innovation and future therapeutic strategies in dyslipidemia”.
Dr. Ramon Eritja, explained the mechanism of action of some new drugs based on small DNA or RNA fragments and especially the mechanism of action of Inclisiran (Leqvio®). This new medicine developed by Novartis received a positive report from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of familial hypercholesteria. It is the first time that this type of medicine has received a positive report for the treatment of a very prevalent disease that is one of the causes of cardiovascular diseases.